Confidence Starts Now
Until now, no stratification test existed for Triple Negative Breast Cancer (TNBC) Patients. The lack of a test that is able to stratify patients by the likelihood of treatment response, meant that every TNBC Patient would get the same treatment option. We knew this was not ideal, but we had no way of knowing who would and who would not achieve a complete response to treatment until we studied Housekeeping Genes.
It took 8 years to answer the question: Which TNBC Patients would not achieve a complete response to the standard-of-care chemotherapy? Part of the answer was found in what are called Housekeeping Genes – the genes responsible for maintaining the minute-by-minute clockwork in breast tissue cells. Surprisingly, when the Triple Negative Cancer Cells prohibit Housekeeping Genes from doing their jobs, the tumor’s response to the standard-of-care chemotherapy changes.
Combining this discovery with others, Bioarray Genetics created the BA100 Triple Negative Breast Cancer Stratification Test. Using the BA100 test, we not only know that approximately 67% of Triple Negative Breast Cancer Patients will not achieve a complete response to the standard-of-care chemotherapy, but we can identify who they are. Wouldn’t you like to know too?
Know Your Response
BA100 is now available to select Oncologists and Patients throughout the United States. This is our first step in making the test available around the world. For a test of this importance, it is critical we understand how it will change the practice of medicine for the roughly 67% who will not achieve a complete response to the standard-of-care chemotherapy. To learn how to get the test, click the button below.
2018 Estimated U.S. Breast Cancer Incidence
2018 U.S. Breast Cancer Cases
2018 U.S. Triple Negative Cases
2018 U.S. HER2+ Cases
2018 U.S. ER+ Cases
Patients and Oncologists
Learn about the people we serve: the Patients and Oncologists on the front line of the battle against Triple Negative Breast Cancer
Housekeeping Genes and Machine Learning
Learn how our unique panel of genes and machine learning algorithms can give Oncologists and TNBC Patients greater confidence.
Investors and Partners
Want to help us bring the world’s first and only Triple Negative Breast Cancer stratification test to the world?
It Takes A
Learn about the team of scientists, clinicians, and professionals who have committed 8 years to crack the code of TNBC stratification.
“To do something that has never been done before, you have to think like nobody else has done before. For us, that meant being inclusive of everyone in the Triple Negative Breast Cancer community and committing to each other to use a different lens in understanding the problem of stratification. Once we understood the power of the context of these cancers, we knew it would only be a matter of time before we found the answer. We looked at cancer in reverse to help those looking forward to a complete response to their treatment.”
We seek to transform cancer treatment decisions and outcomes using gene profiling to provide clinically actionable results to clinicians and patients